Allison Betof Warner, MD, PhD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with stage IIB and beyond melanoma.
BNT111/Cemiplimab Combo Significantly Improves ORR in Unresectable Melanoma
The safety profile of BNT111 plus cemiplimab was consistent with previous trials assessing BNT111 with anti–PD-L1 treatments.
Dabrafenib/Trametinib Yields Sustained Survival During Long-Term Follow-up in Advanced Melanoma
Continued survival was observed in dabrafenib/trametinib combination after 8 years follow-up in patients with advanced melanoma.
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
Omid Hamid, MD, gives his perspective on the use of tumor-infiltrating lymphocyte therapy for patients with melanoma.
Early FDG PET/CT Scanning May Predict Treatment Response in Melanoma
Imaging after 1 week of treatment with pembrolizumab may help identify treatment responses in patients with metastatic melanoma.